Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continuing throughout the first half of 2024: 116 patients enrolled at end of June 2024; Record monthly enrollment with nine patients enrolled in June; Thirty-five patients enrolled in 2024 so far - represents the most robust enrollment rates since the start of the Tigris study; With 34 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial Trial Sites: Currently 23 clinical sites; Recently onboarded the Thomas Jefferson University; an experienced, high-quality site from the EUPHRATES trial; Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible.